Insmed Incorporated is a biopharmaceutical company focused on development and commercialization of drug formulations for treatment of metabolic diseases and endocrine disorders. The company, located in Glen Allen, Va., focuses on correcting metabolic defects in human body by replacing key proteins physiologically. It develops drugs that modulate insulin-like growth factor-1 activity in human body. Insmed Incorporated offers various drug candidates, such as recombinant human IGF-1 bound to protein-3, and IPLEX, which is mecasermin rinfabate injection for treatment of growth failure in children with severe IGF-I deficiency. The company also offers anti-cancer drugs, such as recombinant human insulin-like growth factor binding protein-3, and INSM-18. It develops drugs to treat indications in metabolic and oncology fields.